Allow me to share my notes so you may make a note if you wish? You’re welcome! Hehehe
$Gain Therapeutics(GANX.US$ EOY OR 1Q 2024 Upcoming Milestones ● Completion of the single ascending dose part of the Phase 1 clinical trial of GT-02287 expected late Q4 or early Q1 2024, with demonstration of safety and tolerability of GT-02287 after single administration. ● Completion of the multiple ascending dose part of the Phase 1 clinical trial of GT-02287 expected in Q2 2024, with demonstration of safety and tolerability of GT-02287 after 14-day treatment, and the potential to provide early clinical proof-of-concept of GT-02287 target engagement in human subjects. ● Initiation of first-in-patient proof of concept study in H2 2024, with demonstration of safety and tolerability of GT-02287 in Parkinson’s patients after 3-month treatment, and the potential to provide biomarker-based clinical proof-of-concept of GT-02287.![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : Very important study
TrytosaveabitOP Jaguar8: Yup yup! And info could be soon?
Jaguar8 TrytosaveabitOP: Eggzoited in